Chloroquinoline-acetamide hybrids: A promising series of potential antiprotozoal agents

View Article Online

View Journal

RSC Advances

This article can be cited before page numbers have been issued, to do this please use: A. inam, R. L. Van

Zyl, N. J. van Vuurenb, C. Chen, F. Avecilla, S. M. Agarwal and A. Azam, RSC Adv., 2015, DOI:

10.1039/C5RA05472A.

This is an Accepted Manuscript, which has been through the

Royal Society of Chemistry peer review process and has been

accepted for publication.

Accepted Manuscripts are published online shortly after

acceptance, before technical editing, formatting and proof reading.

Using this free service, authors can make their results available

to the community, in citable form, before we publish the edited

article. This Accepted Manuscript will be replaced by the edited,

formatted and paginated article as soon as this is available.

You can find more information about Accepted Manuscripts in the

Information for Authors.

Please note that technical editing may introduce minor changes

to the text and/or graphics, which may alter content. The journal’s

standard Terms & Conditions and the Ethical guidelines still

apply. In no event shall the Royal Society of Chemistry be held

responsible for any errors or omissions in this Accepted Manuscript

or any consequences arising from the use of any information it

contains.

www.rsc.org/advances

Page 1 of 30

RSC Advances

View Article Online

DOI: 10.1039/C5RA05472A

Chloroquinoline-acetamide hybrids: A promising series of potential

antiprotozoal agent

Afreen Inam^a, Robyn L. Van Zyl^b, Natasha J. van Vuuren^b, Chien-Teng Chen^b, Fernando Avecilla^c, Subhash M.

Agarwal ^d, Amir Azam^a*

In an endeavour to develop efficacious antiprotozoal agents chloroquinoline-acetamide hybrids were

synthesized and screened in vitro against E. histolytica and P. falciparum and Molecular docking

studies were performed against PfDHFR.

Hybrid antimalarial

P. falciparum

CQ resistant 3D7 strain

Cl

N

Piperazine (linker)

Increases hydrophilicity

Amide

( DHFR-Inhibition in

folate biosynthesis)

N

O

HN

(A1-A15)

7-Chloroquinoline

(Accumulation in Haem

binding)

R

Please do not adjust margins

RSC Advances

Page 2 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

ARTICLE

Chloroquinoline-acetamide hybrids: A promising series of potential

antiprotozoal agent

Received 00th January 20xx,

Accepted 00th January 20xx

Afreen Inam^a, Robyn L. Van Zyl^b, Natasha J. van Vuuren^b, Chien-Teng Chen^b, Fernando Avecilla^c,

Subhash M. Agarwal ^d, Amir Azam^a*

DOI: 10.1039/x0xx00000x

www.rsc.org/

Abstract: In an endeavour to develop efficacious antiprotozoal agents 2-[4-(7-chloroquinolin-4-yl)piperazin-1-

yl]acetamide derivatives were synthesized and screened in vitro against the HM1:IMSS strain of E. histolytica and 3D7

strain of P. falciparum. Among the twenty-seven synthesized compounds, eleven evinced propitious anti-amoebic activity

with IC₅₀values ranging from 0.41 to 1.80 µM) lower than the standard drug metronidazole (IC₅₀1.80 µM). All the

compounds inhibited the in vitro growth of P. falciparum (IC₅₀range: 0.30-33.52 µM). Compounds A22 and A25 were

found to be the most active antimalarial derivatives, and compound A16 the most active in inhibiting β-haematin

formation; however compound A25 displayed the more favourable safety profile. The crystal structure for the compounds

A7, A8, A12 and A21 was also determined. The molecular docking of crystal resolved inhibitors with PfDHFR allowed

identification of stabilizing interactions within enzyme active site. These compounds affirm potential for further derivatives

to enhance antiprotozoal activity whilst retaining their safety profile

.

^aDepartment of Chemistry, Jamia Millia Islamia, Jamia Nagar, 110 025, New Delhi, India

^bPharmacology Division, Department of Pharmacy and Pharmacology; WITS Research

Institute for Malaria (WRIM), Faculty of Health Sciences, University of Witwatersrand,

Johannesburg 2193, South Africa

^cDepartamento de Química Fundamental, Universidade da Coruña, Campus da

Zapateira, 15071 A Coruña, Spain.

^dBioinformatics Division, Institute of Cytology and Preventive Oncology (ICMR) I-7,

Sector-39, Noida 201301, Uttar Pradesh, India

This journal is © The Royal Society of Chemistry 20xx

*To whom correspondence should be addressed: tel.: +91 11 2698 1717/3254; fax: +91

J. Name., 2015, 00, 1-3 | 1

11 2698 0229; e-mail address: amir_sumbul@yahoo.co.in

Please do not adjust margins

RSC Advances

Page 3 of 30

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Introduction

Journal Name

Two protozoal diseases, namely, amoebiasis and malaria continue to result in morbidity and mortality

particularly in tropical countries. Amoebiasis is a common problem in areas with poor sanitary conditions and

health education. Whilst over 200 million episodes of malaria occur annually, with approximately 600,000

deaths every year mainly among children and pregnant women in sub-Saharan Africa [1–4]. The main

challenge in malaria control is that the malaria parasite has developed clinically significant resistance to many

classes of drugs [5, 6], and in the recent years to artemisinin-derived antimalarials [7, 8]. To improve the

efficacy and delay the onset of resistance, artemisinin combination chemotherapy (ACT) is a promising

strategy in which an artemisinin derivative is used together with conventional antimalarial drug [9]. ‘Covalent

biotherapy’ a recent rational approach involves linking two molecules with individual intrinsic activity into a

single agent, thus developing hybrid molecule with dual functionality [10, 11]. The quinoline nucleus has

proven to be a source of drug development for such protozoal infections. Chloroquine is a common drug used

for both Entamoeba and Plasmodium infections [12]. Many natural drugs isolated from the plant Cinchona

officinalis namely quinine, quinidine and quinidinone bearing a quinoline ring are also active against

amoebiasis [13]. Chloroquine and amodiaquine are two 7-chlorquinoline-based drugs effective against malaria,

while iodoquinol is used as a standard drug bearing a quinoline ring also used in the treatment of amoebiasis

[14]. Therefore quinoline-based heterocycles have a momentous role in drug design against protozoal diseases

[15]. In our previous research, some 2-quinoline hydrazones, 2-chloroquinoline chalcones and 7-

chloroquinoline sulphonamides have displayed good antiprotozoal activity [16, 17]. Chloroquinoline

derivatives of similar type have also been previously described in the literature as interesting antimalarial

agents [18]

Dihydrofolate reductase (DHFR) is one of the key enzymes in the folate pathway and is requisite for the

maintenance of proper intracellular concentrations of tetrahydrofolate, a coenzyme involved in the

biosynthesis of purines, pyrimidines, and some amino acids [19]. It remains an attractive target for selective

drug design of novel anticancer, antimalarial and antibacterial agents [20]. It is proposed that 4-

aminochloroquinoline will promote haem binding, piperazine is a tertiary amine which increases the

hydrophilicity and the amide group will act as dihydrofolate reductase (DHFR) inhibitor [21].

In the present study, a series of novel chloroquinoline based hybrid molecules bearing a core active 4-

aminochloroquinoline moiety and substituted acetamide linked together with a piperazine have been designed

using the strategy of linking two scaffolds in a single molecule and are expected to show an enhancement/

amelioration of antiamoebic as well as antimalarial activity.

2. Results and Discussion

2.1. Chemistry

The synthetic pathway leading to formation of 2-[4-(7-chloroquinolin-4-yl)piperazine-1-yl]acetamide hybrids

(A1–A27) is depicted in Scheme 1. The chloro-4-piperazin-1-yl-quinoline was synthesized by aromatic

nucleophilic substitution of piperazine on the commercially available 4,7-dichloroquinoline under refluxing

2 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 4 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

conditions with good yield [17]. Different chloro acetamides (1-27) were synthesized by substitution of the

amine with chloro acetyl chloride [22]. The formation of the final compounds (A1–A27) was achieved by

reacting 7-chloro-4-piperazin-1-yl-quinoline with different chloro-acetamides (1-27) using potassium

carbonate as a base, potassium iodide as catalyst and dimethylformaamide as solvent under refluxing

conditions. All the products were soluble in polar solvents and re-crystallized from dichloromethane/hexane

system. All the compounds are stable in solid states at room temperature. The NMR spectra of all the

1

compounds were recorded in CDCl₃that also favours the proposed structures. The H NMR of the aromatic

chloroacetamides (1-15) showed a broad singlet for –NH in the range δ 7.87-9.27ppm whereas it appeared

upfield for the aliphatic chloroacetamides (23-27) δ 5.20-7.33 ppm. The IR spectrum of the final compounds

(A1-A27) exhibited characteristic absorption band due to carbonyl group in the region 1634-1720 cm^-1. The

structure of the compounds was further confirmed by the ¹H NMR spectral data. A broad singlet in the range δ

8.60-11.79 ppm and a doublet δ 8.71- 8.74 ppm due to –NH was observed for the compounds A1-A15 and

A23-A27 respectively. The signals due to the aliphatic and aromatic proton appeared in the expected region.

All the structures were further confirmed by ¹³C NMR and mass spectral studies and the purity of the

compounds was confirmed by elemental analysis and data was found in accordance with ±0.3%.

2.2. Single crystal structure

Single crystal structures of A7, A8, A12 and A21

The asymmetric unit of A7 contains the piperazine derivative and one water molecule; while the asymmetric units of A8,

A12 and A21, only contains the piperazine derivative. The piperazine rings are in a chair form and hence the molecules

have an extended conformation. Both ring N atoms [N(1) and N(2)] in each compound are bonded in a configuration which

are distinctly pyramidals, with the sum of the C—N—C angles being 340.01(9)º and 330.45 (9)º for A7, 344.07(11)º and

328.96(11)º for A8, 340.05(9)º and 333.38(10)º for A12 and 341.50 (8)º and 332.61(8)º for A21 [23]. Bond lengths and

angles are given in supplementary data.

In A7, the presence of intermolecular hydrogen bonds between the water molecule and nitrogen atoms of the piperazine

derivative, determined the configuration around the C=O bond. In A8 and A12 intramolecular hydrogen bonds between

N(2) and N(3) atoms established the configuration of this part of the molecule (Figure 1). In the solid state the compounds

A7 and A21 form dimers through π-π interactions between chloroquinoline groups (Figure 2-3), through phenyl rings in A7

and through pyridine rings in A21. The distances between centroids are: d_c1-c2= 3.754 Å [c1 (C1I-C2I-C3I-C4I-C20I-C21I), c2

(C1E-C2E-C3E-C4E-C20E-C21E) and repeated for other centroids] in A7, and d_c3-c4= 3.591 Å [c3 (C3A-C4A-C5A-C22A-C23A-

N5A), c4 (C3G-C4G-C5G-C22G-C23G-N5G) and repeated for other centroids]. Compounds A8 and A12 do not show these π-

π interactions.

2.3. Biology

2.3.1. Antiamoebic Activity

The antiamoebic effect was compared with the most widely used antiamoebic medication, namely metronidazole (Mtz)

which had a 50% inhibitory concentration (IC₅₀) of 1.80 µM (Table 2). Three different types of amines viz. substituted

anilines (A1-A15), substituted piperazine (A16-A22) and aliphatic amines (A23-A27) were biologically evaluated against E.

3

Please do not adjust margins

RSC Advances

Page 5 of 30

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

histolytica and the amoebicidal activity results for all the compounds were found to be very promising. The structure–

activity relationship (SAR) showed that compounds (A1–A27) which contained piperazine in the acetamide group, showed

IC₅₀values in the range of 0.52-3.24 µM; whereas for the aromatic and aliphatic amines, the IC₅₀values were in the range of

0.41-17.14 µM and 0.86-18.99 µM, respectively. Compound A20 possessed an IC₅₀value in same order as the one noticed

for the reference drug Mtz. Compounds A11 and A15 showed IC₅₀values less than Mtz whereas A16, A21, A23 were found

to be nearly as active as the standard drug. The aromatic amines showed varied results. None of the ortho substituted

compounds (A2, A6, A12) were found to be active. The para substituted compound A7 (IC₅₀0.41±0.02 µM) was the most

potent of all the compounds screened and shows four folds more activity and the compound A9 (IC₅₀0.72±0.01 µM) shows

greater than two fold activity than the standard drug Mtz. The presence of the bulky group in aromatic amines showed

reduced activity. The bulky nature might have imposed steric hindrance thereby, drastically reducing its efficacy.

Precipitous decrease in activity was observed for bulky compound (A13; IC₅₀17.14±0.02 µM) showing ten folds higher value

than Mtz. Compounds containing acetoxy group (A2; IC₅₀7.90±0.02 µM), bromo (A11; IC₅₀7.20±0.02 µM) and chloro-fluoro

disubstituted (A15; IC₅₀7.30±0.01 µM) showed four folds whereas chloro substituted (A10; IC₅₀5.90±0.02 µM) showed

three folds higher IC₅₀values than Mtz and can be considered of less interest. It can be concluded that the piperazine

containing substituents (A16-A21) in the acetamide group showed the best results in the series with the IC₅₀ranging from

0.52-3.24 µM.

2.3.2. Antimalarial and Cytotoxic Activity

All compounds (A1-A27) were active against 3D7 strain of P. falciparum (IC₅₀range: 0.30-33.52 µM), with the most active

compounds A22 (IC₅₀: 0.35 µM) and A25 (IC₅₀: 0.30 µM) almost nine fold more active than the next most active compound

A8 (IC₅₀: 2.84 µM) (Table2). In comparison to chloroquine (IC₅₀: 0.0013 µM),, compounds A22 and A25 were on average

250 times less active in inhibiting parasite growth. The closure of the triangular side chain of the isopropyl compound A24

resulted in a 60 fold increase in antimalarial activity for the cyclopropyl compound A25. Whilst a methyl group in the para

position in the aromatic amine (A8) increased the antimalarial activity 33 fold when compared to the meta (A9) and ortho

(A12) substitutions. In contrast, the positioning of the side groups in compounds A4/A5 and A6/A7 did not greatly alter the

inhibitory activity. As with the antiamoebic activity, the introduction of bulker groups did not improve the antimalarial

activity. Similarly, the addition of halogens (Cl-, F- or Br-) on the aromatic amines did not decrease the IC₅₀values nor did

they aid in binding to the haemin molecules to prevent β-haematin crystal formation (Table 2).

All but one (A20) of the compounds inhibited β-haematin formation to varying degrees, being 1.13-12.51 fold less active

than chloroquine (Table 2) – thus indicating that the 4-aminochloroquinoline group retained some ability to bind to the

haem units as proposed. There was no correlation between the inhibitory effects of the compounds on the whole parasite

and β-haematin formation (r²= 0.019). The most active compounds (A22 and A25) did not primarily inhibit parasite growth

by preventing β-haematin or haemozoin formation, and were found two fold less active than chloroquine (IC₅₀: 15.32 µM).

As such, the antimalarial activity could be due to the effect of the acetamide group on folic acid synthesis and needs to be

investigated. The ability of the most potent compound A16 (IC₅₀: 17.27 µM) to inhibit β-haematin formation was greatly

diminished when compared to the other halogen substituted compounds (A6, A7, A10, A11, A15; IC₅₀range: 44.86-75.51

µM). The equipotent activity of A16 to that of chloroquine was also lost when the compound was tested against the whole

parasite where the IC₅₀value (11.72 µM) increased greatly compared to chloroquine (9020 fold).

Of the 27 derivatives, 17 were more toxic than the dihydrofolate reductase inhibitor, methotrexate and all were more toxic

than chloroquine when tested against the human kidney epithelial cells (Table 2). These 27 derivatives were also more

4 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 6 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

toxic than cycloguanil and pyrimethamine which inhibited approximately 20% cell growth at 100 µg/ml (data not shown).

The most toxic derivative was A2 (34% more toxic than methotrexate), whilst the least toxic was A26; with both of these

derivatives not affecting red blood cell membrane stability (lysis ratio of 0.98 and 0.45, respectively). In contrast the

derivatives which induced the most red blood cell lysis was A21 (lysis ratio 1.96) and least lytic A13 and A2 with a lysis ratio

of 0.28 for both derivatives. Of the halogen substituted derivatives, overall the fluoro-substitutions were 1.6 fold less toxic

to the human kidney epithelial cells compared to chloro- and bromo- substituted derivatives (Table 2). Of the two most

active compounds, compounds A25 displayed the better safety profile when the inhibitory effect on the human kidney

epithelial cells and haemolytic effects (40.07% inhibition; 0.78 lysis ratio) are compared to those of chloroquine (1.05%

inhibition; 1.0 lysis ratio) and A22 (70.78% inhibition; 1.65 lysis ratio) (Table 2). The latter indicated that compound A25 did

not alter the host red blood cell membrane integrity, and that the antimalarial activity was directed towards the intra-

erythrocytic parasite. Both A22 and A25 had a higher selectivity for the malaria parasite compared to the human cell. But

overall the safety profile for A25 indicates that it has potential for further structural modifications to improve both

antimalarial and cytotoxic activity.

2.4 Molecular Docking

The hybrid molecules capable of exhibiting dual activity i.e. β-haematin and DHFR inhibition have been designed and a

homology model of PfDHFR was also generated so as to analyze the interactions of the quinoline based acetamides with

the enzyme. The binding mode of four active analogues (A7, A8, A18 and A21) using the crystal structure has been

predicted to understand the protein-ligand contacts and their interaction strength docking of these compounds along with

WR99210, the co-crystallised compound in the active site of wild PfDHFR. The root-mean-square deviation (RMSD)

between the re-scored docked ligand and original X-ray crystallised ligand WR99210 was observed to be 1.19 Å validating

the docking protocol. The three compounds A7, A8 and A18 exhibited similar pose as that of co-crystallised ligand

WR99210 in the binding region (Figure4). The Autodock binding energy of A7, A8, A18 and A21 is -9.34 kcal/mol, -9.90

kcal/mol, -9.67 kcal/mol and -9.57 kcal/mol respectively, in comparison to binding energy of -10.86 kcal/mol for WR99210

ligand bound to crystal of PfDHFR. The interaction plots generated using Ligplot (Figure 4) indicated that the three ligands

(A7, A8 and A18) exhibit H-bonding with Ile 164 similar to that observed in WR99210. Also, all the four compounds showed

highly conserved hydrohophobic interactions with the same active site residues Ile14, Cys15, Val45, Leu46, Lys49, Asp54,

Met55, Phe58, Ser111 and Ile112, expect a few exceptions in case of A21, which is due to difference in the orientation of

compound within the active site of the enzyme. The molecular docking data thus provides us insight into the binding

modes of ligands in the active site of PfDHFR.

Experimental

Most the chemicals were purchased from Aldrich Co (USA). Precoated aluminum sheets (silica gel 60 F254, Merck,

Germany) were used for thin-layer chromatography (TLC) and spots were visualized under UV light. The melting points

were recorded on Buchi melting point apparatus Model No.650 and were uncorrected. Elemental analyses were

performed in an Elementar Vario analyzer and the results lay within ± 0.3% of the theoretical values. IR spectra were

1

acquired at Bruker FT-IR spectrophotometer. H and ¹³C NMR were recorded on a Bruker Spectrospin DPX 300 MHz and

Bruker Spectrospin DPX 75 MHz spectrometer respectively, using CDCl₃as a solvent and trimethylsilane (TMS) as the

internal standard. Splitting patterns are designated as follows; s, singlet; d, doublet; t, triplet; m, multiplet, bs, broad

singlet, ss, sharp singlet. Electrospray (ES) mass spectra were carried out on Microtof-Q II 10262. Melting points were

recorded on a Veego melting point apparatus (model REC-2203882) and were uncorrected.

5

Please do not adjust margins

RSC Advances

Page 7 of 30

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

5.1. Preparation of 7-chloro-4-(piperazin-1-yl)quinoline (2) 7-chloro-4-(piperazin-1-yl)quinoline was prepared by the

reported method [17].

5.2. General procedure for the preparation of different substituted chloro acetamides The aromatic and aliphatic

acetamides were prepared by two different methods as given below:

For substituted aromatic acetamides: To a stirring solution of anilines in glacial acetic acid.50% aqueous sodium acetate,

chloro acetyl chloride was added dropwise. The reaction mixture was stirred at room temperature for 4 hrs. The product

was precipitated by adding reaction mixture to crushed ice and was filtered on a Buckner funnel. The product formed was

recrystallized in ethanol (1-15). These compounds have already been reported in the following literature [24-32]

For aliphatic (2-Chloro-acetamides): To a stirring solution of amine in 10 ml dichloromethane, triethylamine was added.

The reaction mixture was cooled to 0°C (under ice bath) and chloroacetyl chloride was added. The reaction mixture was

then stirred for 3-4 hrs at room temperature and partitioned between water and dichloromethane. Organic extract was

separated and dried on sodium sulphate and concentrated to yield acetylated products (16-27). All the compounds are

already reported in the literature [33-40] except Compound 19 and 21 whose spectral data is given in the supplementary

information.

5.3 Synthesis of the 2-[4-(7-chloroquinolin-4-yl)piperazine-1-yl]acetamide derivatives: general synthesis

A mixture of 7-chloro-4-(piperazin-1-yl)quinoline(2) (1.0 eq), Chloroacetamides (1-27) (1.1eq) , K₂CO₃(2.5eq) and catalytic

amount of potassium iodide in dimethyl formamide was refluxed at 90°C for 8-10 hrs with continuous stirring. After

reaction completion (monitored by TLC) the mixture was poured on crushed ice. The product precipitated was filtered over

buckner funnel and was recrystallized from appropriate solvent.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-phenylacetamide (A1): Yield 64% colourless solid m.pt. 157-160^°C ; H¹NMR

(CDCl₃) δppm: 9.05 (s, 1H), 8.76 (d, 1H, J=7.8Hz), 8.06 (s, 1H), 7.96 (d, 1H, J=9.0Hz), 7.60(d, 2H, J=7.8Hz), 7.47-7.43(m, 1H),

7.38(t, 2H, J=7.8Hz), 7.16 (t, 1H, J=7.5Hz), 6.89 (d, 1H, J=5.1Hz), 3.31(bs, 4H), 3.30 (s, 2H), 2.96-2.88 (m, 4H); ¹³C NMR

(CDCl₃) δppm: 167.83, 156.59, 151.84, 150.08, 137.45, 135.10, 129.90, 128.88, 126.43, 125.01, 124.41, 121.83, 119.52,

109.12, 62.05, 53.40, 52.29; IR (υ_max) cm^-1: 3255, 1658, 1542; ESI-MS: m/z 381.13 (M+1); Anal. Calc. for C₂₁H₂₁N₄OCl; C

66.22, H 5.56, N 14.71, found C 66.52, H 5.60, N 14.63%.

Methyl 2-(2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)acetamido)benzoate(A2): Yield 73% yellow solid m.pt. 128-131^°C;

H¹NMR (CDCl₃) δppm: 11.79 (s, 1H), 8.72-8.64 (m, 2H), 8.06-7.97 (m, 3H), 7.64-7.53 (m, 2H), 7.201 (t, 1H, J=7.5 Hz), 7.05 (d,

1H, J=4.8Hz), 3.88 (s, 3H), 3.36 (bs, 4H), 3.31 (s, 2H), 2.89 (bs, 4H); ¹³C NMR (CDCl₃) δppm: 169.64, 167.80, 156.99, 151.91,

150.21, 140.70, 134.93, 134.39, 130.87, 128.90, 126.18, 125.20, 122.77, 121.93, 120.60, 115.91, 109.00, 62.68, 53.44,

52.15, 51.92; IR (υ_max) cm^-1: 3315, 1686, 1572; ESI-MS: m/z 439.15 (M+1); Anal. Calc. for C₂₃H₂₃N₄O₃Cl, C 62.94, H 5.28, N

12.76, found C 62.16, H 5.28, N 12.55%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-(2,5-difluorophenyl)acetamide (A3): Yield 78% colourless solid m.pt. 183-

187^°C; H¹NMR (CDCl₃) δppm: 9.59 (bs, 1H), 8.76 (d, 1H, J=4.8Hz), 8.27-8.20 (m, 1H), 8.06 (s, 1H), 7.95 (d, 1H, J=9.0Hz),

7.46(d, 1H, J=8.1Hz), 7.09-7.01(m, 1H), 6.90 (d, 1H, J=4.8Hz), 6.77-6.72(m, 1H), 3.34(bs, 4H), 3.19(s, 2H), 2.96(bs, 4H); ¹³C

NMR (CDCl₃) δppm: 168.86, 156.73, 151.95, 150.18, 138.57, 134.10, 133.94, 130.89, 129.58, 127.58, 121.76, 120.75,

115.47, 111.01, 110.91, 108.76, 61.98, 54.73, 54.27, 53.78, 52.90; IR (υ_max) cm^-1: 1688, 1573 ; ESI-MS: m/z 417.06 (M+1);

Anal. Calc. for C₂₁H₁₉N₄OClF; C 60.51, H 4.59 N 13.44, found C 60.50, H 4.45, N 13.40%.

6 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 8 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

N-(3-acetylphenyl)-2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)acetamide(A4): Yield 65% yellow solid m.pt. 152-156^°C; H¹

NMR (CDCl₃) δppm: 9.29 (s, 1H), 8.85-8.77 (m, 1H), 8.07-7.93 (m, 4H), 7.73 (d, 1H, J=6.9Hz), 7.49 (t, 2H, J=7.2Hz), 6.96-

6.91(m, 1H), 3.33 (bs, 4H), 3.31 (s, 2H), 2.96 (bs, 4H), 2.63 (s, 3H); ¹³C NMR (CDCl₃) δppm: 198.14, 169.07, 156.77, 152.62,

150.11, 139.48, 137.79, 134.04, 129.54, 128.50, 126.52, 124.52, 123.92, 121.84, 119.27, 109.87, 61.99, 52.97, 52.08, 27.19;

IR (υ_max) cm¹:3295, 1726, 1671, 1568; ESI-MS: m/z 423.16 (M+1); Anal. Calc. for C₂₃H₂₃N₄O₂Cl; C 65.32, H 5.48 N 13.25,

found C 65.52, H 5.630, N 13.33%.

N-(4-acetylphenyl)-2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)acetamide(A5): Yield 54% yellow solid m.pt. 130-133^°C; H¹

NMR (CDCl₃) δppm: 9.28 (s, 1H), 8.77 (s, 1H), 8.070-7.92 (m, 4H), 7.71 (d, 2H, J= 7.8Hz), 7.47-7.44 (m, 1H), 6.90 (d, 1H,

J=5.1Hz), 3.33 (bs, 4H), 3.31 (s, 2H), 2.97 (bs, 4H), 2.59 (s, 3H); ¹³C NMR (CDCl₃) δppm: 196.83, 168.25, 156.50, 151.84,

150.07, 141.68, 135.10, 133.04, 129.78, 128.89, 126.46, 124.96, 121.80, 118.74, 109.15, 62.06, 53.44, 52.25, 26.43; IR

(υ_max) cm^-1: 3238, 1783, 1676, 1585; ESI-MS: m/z 423.06 (M+1); Anal. Calc. for C₂₃H₂₃N₄O₂Cl; C 65.32, H 5.48 N 13.25, found

C 65.40, H 5.47, N 13.70%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-(2-fluorophenyl)acetamide (A6): Yield 68% solid m.pt. 133-136^°C; H¹NMR

(CDCl₃) δppm: 9.511(s, 1H), 8.76 (d, 1H, J=4.8Hz), 8.41 (t, 1H, J=7.8Hz), 8.06 (s, 1H), 7.96 (d, 1H, J=9.0Hz), 7.46 (d, 1H,

J=9.3Hz), 7.18-7.08(m, 3H), 6.90(d, 1H, J=5.1Hz), 3.33 (bs, 4H), 3.31(s, 2H), 2.97 (bs , 4H); ¹³C NMR (CDCl₃) δppm:167.95,

156.55, 154.11, 151.91, 150.89, 135.03, 128.97, 126.38, 125.96, 124.98, 124.65, 124.45, 121.85, 121.32, 114.95, 109.20,

61.98, 53.35, 52.34; IR (υ_max) cm^-1: 3296, 1690, 1572 ; ESI-MS: m/z 399.52 (M+1); Anal. Calc. for C₂₁H₂₀N₄OClF; C 63.24, H

5.05, N 14.05, found C 63.04, H5.15, N14.25%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-(4-fluorophenyl)acetamide (A7): Yield 84% yellow solid m.pt. 125-128^°C;

H¹NMR (CDCl₃) δppm: 9.08 (s, 1H), 8.76 (d, 1H, J=4.8Hz), 8.06 (s, 1H), 7.95 (d, 1H, J=9 Hz), 7.57-7.53 (m, 2H), 7.47-7.44 (m,

1H), 7.07 (d, 2H, J=9Hz), 6.88 (d, 1H, J=5.1Hz), 3.23 (bs , 4H), 3.30 (s, 2H), 3.04 (bs, 4H); ¹³C NMR (CDCl₃) δppm: 167.80,

161.01, 157.78, 156.56, 151.85, 150.10, 135.12, 133.48, 128.90, 126.46, 124.92, 121.84, 121.31, 115.86, 115.56, 109.12,

61.93, 53.44, 52.27; IR (υ_max) cm^-1: 3255, 1686, 1502; ESI-MS: m/z 399.52 (M+1); Anal. Calc. for C₂₁H₂₀N₄OClF; C 63.24, H

5.05, N 14.05, found C 63.14, H5.09, N 14.25%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-p-tolylacetamide (A8): Yield 62% colourless solid m.pt. 157-160^°C; H¹NMR

(CDCl₃) δppm: 9.71(s, 1H), 8.72 (d, 1H, J= 4.8 Hz), 8.04-7.99 (m, 2H), 7.56 (d, 3H, J=7.5Hz), 7.13(d, 2H, J=7.8Hz), 7.03 (d, 1H,

J= 5.1Hz), 3.26 (bs, 4H), 3.23 (s, 2H), 2.83 (bs, 4H), 2.25 (s, 3H); ¹³C NMR (CDCl₃) δppm: 167.64, 156.57, 151.91, 150.17,

135.08, 134.90, 134.05, 129.57, 128.97, 126.44, 124.99, 121.86, 119.54, 109.13, 62.05, 53.43, 52.31, 20.88; IR (υ_max) cm^-1:

3296, 1676, 1572; ESI-MS: m/z 395.11 (M+1); Anal. Calc. for C₂₂H₂₃N₄OCl; C 66.91, H 5.87, N 14.19, found C 66.89, H 5.97,

N 14.09%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-m-tolylacetamide (A9): Yield 65% yellow solid m.pt. 100-103^°C; H¹NMR

(CDCl₃) δppm: 9.00 (s, 1H), 8.76 (d, 1H, J= 5.1 Hz), 8.06 (d, 1H, J=1.8 Hz), 7.96 (d, 1H, J=9Hz), 7.47-7.41 (m, 3H), 7.24 (d, 1H,

J=7.8Hz), 6.96 (d, 1H, J=7.8 Hz), 6.89 (d, 1H, J= 5.1 Hz), 3.32 (bs, 4H), 3.29 (s, 2H), 2.95 (bs, 4H), 2.36 (s, 3H);¹³C NMR (CDCl₃)

δppm: 167.84, 156.82, 151.35, 150.27, 135.48, 134.63, 130.39, 128.47, 126.49, 124.84, 124.45, 121.75, 119.55, 117.48,

109.40, 61.89, 53.45, 52.30, 19.79; IR (υ_max) cm^-1: 3275, 1665, 1570; ESI-MS: m/z 395.19 (M+1); Anal. Calc. for C₂₂H₂₃N₄OCl;

C 66.91, H 5.87, N 14.19, found C 66.71, H 5.78, N 14.09%.

N-(3-chlorophenyl)-2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)acetamide(A10): Yield 65% white solid m.pt. 131-135^°C; H¹

NMR (CDCl₃) δppm: 9.09 (s, 1H), 8.76 (d, 1H, J= 4.8 Hz), 8.06 (s, 1H), 7.95 (d, 1H, J= 9Hz), 7.66 (s, 1H), 7.46 (d, 1H, J=7.2 Hz),

7.29 (d, 2H, J= 8.4 Hz), 7.12 (d, 1H, J=7.2 Hz), 6.89 (d, 1H, J=4.5Hz), 3.30 (bs, 4H0, 3.20 (s, 2H), 2.94(bs, 4H); ¹³C NMR (CDCl₃)

7

Please do not adjust margins

RSC Advances

Page 9 of 30

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

δppm: 167.94, 156.49, 151.90, 150.17, 138.60, 135.09, 134.73, 130.10, 128.97, 126.46, 124.94, 124.41, 121.85, 119.54,

117.46, 109.16, 61.98, 53.44, 52.27; IR(υ_max)cm^-1: 3087, 1687, 1580 ; ESI-MS: m/z 416.03 (M+1); Anal. Calc. for

C₂₁H₂₀N₄OCl₂; C 60.73, H 4.85, N 13.49, found C 60.79, H 4.97, N 13.29%.

N-(4-bromophenyl)-2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)acetamide (A11): Yield 68% colourless solid m.pt. 188-

191^°C; H¹NMR (CDCl₃) δppm: 9.76(bs, 1H), 8.72 (d, 1H, J=4.8Hz), 8.05-7.92(m, 4H), 7.55(d, 1H, J=8.4Hz), 7.31-7.28 (m, 1H),

7.03-6.97(m, 2H), 3.36(bs, 4H), 3.26(s, 2H), 2.88(bs, 4H); ¹³C NMR (CDCl₃) δppm: 168.88, 156.75, 152.60, 150.10, 138.46,

134.03, 131.90, 128.50, 126.49, 126.20, 121.94, 121.36, 115.49, 109.85, 61.97, 52.95, 52.07; IR (υ_max) cm^-1: 1663, 1576 ;

ESI-MS: m/z 460.28 (M+1); Anal. Calc. for C₂₁H₂₀N₄OBrCl; C 54.86, H 4.38 N 12.19, found C 54.98, H 4.60, N 12.19%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-o-tolylacetamide (A12): Yield 78% colorless solid m.pt. 178-181^°C; H¹NMR

(CDCl₃) δppm: 9.20(bs, 1H), 8.79(d, 1H, J=5.1Hz), 8.15(d, 1H, J=8.1Hz), 8.06(s, 1H), 7.96(d, 1H, J=9.0Hz), 7.47-7.43(m, 1H),

7.22-7.18(m, 2H), 7.13-7.04(m, 1H), 6.89(d, 1H, J=5.1Hz), 3.34(bs, 4H), 3.32(s, 2H), 3.00(bs, 4H), 2.31(ss, 3H); ¹³C NMR

(CDCl₃) δppm:167.57, 156.47, 151.89, 150.16, 135..65, 135.08, 130.41, 128.96, 127.03, 126.98, 126.44, 124.99, 121.82,

121.15, 109.12, 62.17, 53.47, 52.46, 17.83l; IR (υ_max) cm^-1:1684, 1576; ESI-MS: m/z 395.19 (M+1); Anal. Calc. for

C₂₂H₂₃N₄OCl; C 66.91, H 5.87 N 14.91 found C 66.89, H 5.97, N 14.30%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-(naphthalen-1-yl)acetamide(A13): Yield 80% colourless solid m.pt. 180-

183^°C; H¹NMR (CDCl₃) δppm: 9.76 (s, 1H), 8.78 (d, 1H, J=4.8Hz), 8.27 (d, 1H, J=7.5Hz), 8.07 (s, 1H), 7.99 (d, 1H, J=7.4Hz),

7.89-7.79 (m, 2H), 7.70 (d, 1H, J=7.5Hz), 7.56-7.48 (m, 4H), 6.93 (d, 1H, J=5.1Hz), 3.46 (bs, 4H), 3.31 (s, 2H), 3.08 (bs, 4H),

¹³C NMR (CDCl₃) δppm: 168.01, 156.48, 151.93, 150.20, 135.10, 134.11, 132.08, 129.07, 129.01, 126.37, 126.02, 125.97,

125.08, 124.99, 121.84, 119.67, 118.64, 109.15, 62.35, 53.57, 52.48; IR (υ_max) cm^-1:3280, 1690, 1571; ESI-MS: m/z 431.24

(M+1); Anal. Calc. for C₂₅H₂₃N₄OCl; C 69.68, H 5.38 N 13.00, found C 69.80, H 5.27, N 13.00%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-(2,6-dimethylphenyl)acetamide (A14): Yield 76% colorless solid m.pt. 168-

171^°C; H¹NMR (CDCl₃) δppm: 8.75(d, 1H, J=4.8Hz), 8.60(bs, 1H), 8.06(s, 1H), 7.97(d, 1H, J=8.7Hz), 7.47-7.43(m, 1H), 7.12-

7.11(m, 3H), 6.87(d, 1H, J=5.1Hz), 3.37(s, 2H), 3.32(bs, 4H), 3.03(bs, 4H), 2.25(ss, 6H); ¹³C NMR (CDCl₃) δppm: 168.38,

156.76, 152.64, 150.13, 135.64, 135.48, 134.03, 128.51, 128.10, 126.86, 126.55, 126.19, 121.85, 109.85, 61.59, 53.29,

52.07, 18.72; IR (υ_max) cm^-1:1661, 1573; ESI-MS: m/z 409.33 (M+1); Anal. Calc. for C₂₃H₂₅N₄OCl; C 67.56, H 6.16 N 13.70,

found C 67.65, H 6.56, N 13.61%.

N-(3-chloro-4-fluorophenyl)-2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)acetamide (A15): Yield 76% colorless solid m.pt.

177-180^°C ; H¹NMR (CDCl₃) δppm: 9.07(bs, 1H), 8.76(d, 1H, J=5.1Hz), 8.06(s, 1H), 7.95(d, 1H, J=9.0Hz), 7.75-7.72(m, 1H),

7.47-7.43(m, 2H), 7.14(m, 1H), 6.89(d, 1H, J=4.8Hz), 3.30(bs, 4H), 3.19(s, 2H), 2.95(bs, 4H); ¹³C NMR (CDCl₃) δppm: 169.01,

167.37, 156.76, 152.58, 150.11, 134.04, 132.20, 131.95, 129.11, 128.50, 126.48, 121.84, 120.79, 119.65, 117.37, 109.83,

61.90, 52.95, 52.04; IR (υ_max) cm^-1: 3292, 1693, 1573 ; ESI-MS: m/z 434.36 (M+1); Anal. Calc. for C₂₁H₁₉N₄OCl₂F; C 58.21, H

4.42 N 12.93, found C 58.01, H 4.22, N 12.73%.

1-(4-benzylpipezin-1-yl)-2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)ethanone(A16): Yield 44% white solid m.pt. 135-

138^°C; H¹NMR (CDCl₃) δppm: 8.72 (d, 1H, J=5.1Hz), 8.04 (s, 1H), 7.95 (d, 1H, J=9Hz), 7.44-7.40 (m, 2H), 7.33-7.31 (m, 4H),

6.84 (d, 1H, J=5.1Hz), 3.64 (d, 4H, J=3.6Hz), 3.52 (s, 2H), 3.35 (bs, 4H), 3.32 (s, 2H), 2.28 (d, 4H, J=4.2 Hz), 2.46 (d 4H,

J=4.5Hz); ¹³C NMR (CDCl₃) δppm: 167.58, 156.85, 151.89, 150.17, 137.61, 134.94, 129.08, 128.89, 128.34, 127.29, 126.20,

125.16, 121.90, 108.99, 62.92, 61.02, 53.35, 52.94, 52.11, 45.65, 41.87; IR (υ_max) cm^-1: 1635, 1378, 1275; ESI-MS: m/z

465.01 (M+1); Anal. Calc. for C₂₆H₃₀N₅OCl; C 67.302, H 6.52, N 15.09, found C 67.16, H 6.75, N 15.18%.

8 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 10 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

1-(4-(3-chlorophenylpipezin-1-yl)- 2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)ethanone (A17): Yield 34% colorless solid

m.pt. 116-120^°C; H¹NMR (CDCl₃) δppm: 8.73(d, 1H, J=4.8 Hz), 8.04 (s, 1H), 7.95 (d, 1H, J= 9.0 Hz), 7.45-7.41(m, 1H), 7.19 (d,

1H, J=7.8Hz),6.89-6.79 (m, 4H), 3.79 (bs, 4H), 3.37 (s, 2H), 3.26-3.18 (m, 8H), 2.85( bs, 4H); ¹³C NMR (CDCl₃) δppm: 167.80,

156.48, 151.68, 150.58, 150.23, 134.92, 134.23, 128.89, 127.74, 127.57, 126.22, 125.43, 125.23, 121.78, 119.02, 109.02,

61.17, 52.98, 52.23, 52.01, 51.55, 45.75, 42.32; IR (υ_max) cm^-1: 1634, 1374 ; ESI-MS: m/z 485.43 (M+1); Anal. Calc. for

C₂₅H₂₇N₅OCl₂; C 61.99, H 5.62 N 14.46, found C 61.79, H 5.89, N 14.03%.

tert-butyl 4-(2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)acetyl)piperzine-1-carboxylate (A18): Yield 40% white solid m.pt.

104-107^°C; H¹NMR (CDCl₃) δppm: 8.73(d, 1H, J=4.8Hz), 8.04(bs, 1H), 7.95(, 1H, J=6.0Hz), 7.44 (d, 1H, J=9.0Hz), 6.84 (d, 1H,

J=5.1Hz), 3.61(bs, 4H), 3.48-3.44(m, 4H), 3.34 (s, 2H), 1.59(ss, 9H), 1.47 (s, 8H); ¹³C NMR (CDCl₃) δppm: 168.02, 156.71,

154.28, 152.81, 150.01, 134.00, 128.14, 127.34, 126.80, 125.70, 121.78, 79.61, 60.88, 52.69, 52.22, 45.50, 28.97, 28.48,

27.95; IR (υ_max) cm^-1: 1691, 1300 ; ESI-MS: m/z 474.22 (M⁺); Anal. Calc. for C₂₃H₂₃N₄O₂Cl; C 60.81, H 6.80 N 14.78, found C

60.94, H 6.74, N 14.90%.

1-(4-(benzo[1,3]dioxol -5-yl)methyl)piperzin-1-yl-2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)ethanone (A19): Yield 35%

white solid m.pt. 192-195^°C; H¹NMR (CDCl₃) δppm: 8.72(d, 1H, J=5.1Hz), 8.04(s, 1H), 7.93(d, 1H, J=9.0Hz), 7.73-7.70(m, 1H),

7.54-7.51(m, 1H), 7.43-7.40(m, 1H), 6.93(d, 1H, J=6.6Hz), 6.85(d, 1H, J=4.8Hz), 4.19(s, 2H), 3.26(bs, 4H), 3.12(s, 2H), 2.83(bs,

4H), 1.25(s, 2H), 1.20(bs, 4H),1.09(bs, 4H); ¹³C NMR (CDCl₃) δppm: 168.62, 156.63, 151.84, 150.11, 134.94, 132.35, 130.88,

128.87, 126.27, 125.05, 121.82, 109.03, 71.74, 61.61, 53.33, 52.17, 40.78, 27.68, 22.82, 19.13; IR (υ_max) cm^-1:1672, 1544 ;

ESI-MS: m/z 508.21 (M+1); Anal. Calc. for C₂₇H₃₀N₅O₃Cl; C 63.84, H 5.95 N 13.79, found C 63.47 H 5.55, N 13.75%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl) -1-(4-phenylpipezin-1-yl)-ethanone (A20): Yield 39% colorless solid m.pt. 135-

138^°C; H¹NMR (CDCl₃) δppm: 8.72(d, 1H, J=5.1Hz), 8.04(s, 1H), 7.95(d, 1H, J=9.0Hz), 7.44-7.40(m, 1H), 7.39-7.23(m, 2H),

6.95-6.85(m, 3H), 6.83(d, 1H, J=5.1Hz), 3.82-3.78(m, 4H), 3.38(s, 2H), 3.29-3.17(m, 8H), 2.85(bs, 4H); ¹³C NMR (CDCl₃)

δppm: 167.66, 156.78, 151.88, 150.94, 150.15, 134.93, 129.27, 128.89, 126.21, 125.15, 121.88, 120.59, 116.62, 109.09,

61.16, 52.98, 52.13, 50.10, 49.47, 45.61, 41.78; IR (υ_max) cm^-1: 1652, 1564; ESI-MS: m/z 450.09(M+1); Anal. Calc. for

C₂₅H₂₈N₅OCl; C 66.73, H 6.27 N 15.56, found C 66.70, H 6.68, N 15.44%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-1-(4-(2,3-dichlorophenylpipezin-1-yl)- ethanone (A21): Yield 48% white solid

m.pt. 143-146^°C ; H¹NMR (CDCl₃) δppm: 8.72(d, 1H, J=4.8Hz), 8.04(s, 1H), 7.95(d, 1H, J=8.7Hz), 7.44-7.41(m, 1H), 7.22-

7.13(m, 2H), 6.94-6.91(m, 1H), 6.84(d, 1H, J=5.1Hz), 3.82(bs, 4H), 3.38(s, 2H), 3.26(bs, 4H), 3.06-3.02(m, 4H), 2.85(bs, 4H);

¹³C NMR (CDCl₃) δppm: 167.81, 156.78, 151.90, 150.58, 150.15, 134.92, 134.23, 128.89, 127.74, 127.57, 126.22, 125.23,

125.13, 121.88, 118.72, 109.02, 61.17, 52.98, 52.13, 52.01, 51.25, 45.95, 42.02; IR (υ_max) cm^-1:1645, 1569 ; ESI-MS: m/z

518.94 (M+1); Anal. Calc. for C₂₅H₂₆N₅OCl₃; C 57.85, H 5.05 N 13.50, found C 57.67, H 5.02, N 13.46%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl) 1-(4-hydroxypiperidin-1-yl)- ethanone (A22): Yield 30% green solid m.pt. 102-

105^°C; H¹NMR (CDCl₃) δppm: 8.69(d, 1H, J=4.5Hz), 8.03(s, 1H), 7.93(d, 1H, J=9.0Hz), 7.42(d, 1H, J=9.0Hz), 6.82(d, 1H,

J=4.8Hz), 4.13(s, 1H), 3.96(s, 2H), 3.48-3.24(m, 8H), 2.91-2.81(m, 4H), 2.63(bs, 1H), 2.14-2.01(m, 2H), 1.72-1.50(m, 2H); ¹³

C

NMR (CDCl₃) δppm: 167.57, 156.92, 151.75, 149.97, 134.98, 128.67, 126.22, 125.19, 121.84, 108.98, 66.93, 61.08, 52.96,

52.09, 43.01, 39.33, 34.84, 34.17; IR (υ_max) cm^-1:1720, 1570, ; ESI-MS: m/z 389.09 (M+1); Anal. Calc. for C₂₀H₂₅N₄O₂Cl; C

61.77, H 6.48 N 14.41, found C 61.48, H 6.47, N 14.30%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-cyclohexylacetamide (A23): Yield 44% white solid m.pt. 105-108^°C; H¹NMR

(CDCl₃) δppm: 8.74 (d, 1H, J=5.1Hz), 8.053 (s, 1H), 7.94 (d, 1H, J=9Hz), 7.45 -7.42 (m, 1H), 7.02 (d, 1H, J=6.9Hz), 6.86 (d, 1H,

J=5.1Hz), 3.85 (m, 1H), 3.26 (bs, 4H), 3.13 (s, 2H), 2.85 (bs, 4H), 1.72-1.67 (m, 4H), 1.47-1.35 (m, 2H), 1.26-1.15 (m, 4H); ¹³

C

9

Please do not adjust margins

RSC Advances

Page 11 of 30

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

NMR (CDCl₃) δppm: 168.49, 156.63, 151.86, 150.17, 134.99, 128.93, 126.31, 125.03, 121.85, 109.04, 61.63, 53.35, 52.24,

47.39, 33.12, 25.52, 24.69; IR (υ_max) cm^-1: 3232, 1649, 1573 ; ESI-MS: m/z 387.03 (M+1); Anal. Calc. for C₂₁H₂₇N₄OCl; C

65.19, H 7.03 N 14.48, found C 65.29, H 7.34, N 14.48%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-isopropylacetamide (A24): Yield 42% colorless solid m.pt. 111-114^°C; H¹

NMR (CDCl₃) δppm: 8.72 (d, 1H, J=5.1 Hz), 8.04 (s, 1H), 7.93 (d, 1H, J=9.0Hz), 7.43-7.40 (d, 1H, J=7.2Hz), 6.93(bs, 1H), 6.85

(d, 1H, J=4.8Hz), 4.19-4.07 (m, 1H), 3.26 (bs, 4H), 3.12 (ss, 2H), 2.83-2.82 (m, 4H), 1.25-1.18 (m, 6H) ; ¹³C NMR (CDCl₃)

δppm: 167.58, 151.92, 150.18, 134.00, 131.52, 128.14, 126.80, 125.24, 121.98, 109.34, 62.61, 61.02, 52.94, 52.25, 52.11,

51.40, 45.67, 41.88; IR (υ_max) cm^-1:1642, 1574 ;. Calc. for C₁₈H₂₃N₄OCl; 62.33, H 6.68, N 16.15.70, found C 62.30, H 6.48, N

16.35%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-cyclopropylacetamide (A25): Yield 50% colorless solid m.pt. 101-104^°C; H¹

NMR (CDCl₃) δppm: 8.73 (d, 1H, J= 5.4 Hz), 8.15 (bs, 1H), 8.06 (d, 1H, J=9.0 Hz),7.95 (d, 1H, J=8.4Hz), 7.40 (d, 1H, J=9.0Hz),

6.84 (s, 1H), 3.95 (s. 2H), 3.68-3.66 (m, 1H), 3.21-3.08 (m, 8H), 2.18-2.02 (m, 4H); ¹³C NMR (CDCl₃) δppm: 167.67, 157.23,

151.88, 150.08, 134.92, 129.04, 128.78, 126.18, 121.88, 71.78, 53.11, 45.78, 40.00, 19.13; IR (υ_max) cm^-1: 1662, 1568; ESI-

MS: m/z 345.75 (M+1); Anal. Calc. for C₁₈H₂₁N₄OCl; C 65.32, H 5.48 N 13.25, found C 65.40, H 5.47, N 13.70%.

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-cyclopentylacetamide (A26): Yield 45% white solid m.pt. 108-111^°C; H¹

NMR (CDCl₃) δppm: 8.71 (d, 1H, J=5.1Hz), 8.02-7.97 (m, 2H), 7.72-7.65 (m, 2H), 7.56 (d, 1H, J=7.2Hz), 3.21 (bs, 4H), 3.02 (s,

2H), 2.72 (bs, 4H), 1.81-1.77 (m, 1H), 1.63-1.61 (m, 2H), 1.56-1.50 (m, 2H), 1.43-1.39 (m, 4H); ¹³C NMR (CDCl₃) δppm:

168.58, 155.01, 151.46, 150.28, 133.25, 127.62, 124.93, 123.65, 121.95, 110.54, 62.03, 53.95, 52.44, 48.52, 31.96, 28.94; IR

(υ_max) cm^-1: 1648, 1574; ESI-MS: m/z 373.51 (M+1); Anal. Calc. for C₂₀H₂₅N₄OCl; C 64.42, H 6.76 N 15.02, found C 64.41, H

6.67, N 15.00%.

N-butyl-2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)acetamide (A27): Yield 48% colorless solid m.pt. 128-131°C; H¹NMR

(CDCl₃) δppm: 8.71(d, 1H, J=4.8Hz), 8.03-7.97(m, 2H), 7.77(bs, 1H), 7.57(d, 1H, J=9.0Hz), 7.02(d, 1H, J=4.8Hz), 3.23(bs, 4H),

3.14-3.07(m, 2H), 3.03(s, 2H), 2.72(bs, 4H), 1.44-1.39(m, 2H), 1.31-1.23(m, 2H), .089-.085(m, 3H); ¹³C NMR (CDCl₃) δppm:

169.49, 156.61, 151.85, 150.11, 134.94, 128.86, 126.28, 125.05, 121.82, 109.03, 61.59, 53.41, 52.20, 38.67, 31.76, 20.12,

13.74; IR (υ_max) cm^-1:1662, 1571; ESI-MS: m/z 361.19 (M+1); Anal. Calc. for C₁₉H₂₅N₄OCl; C 63.24, H 6.98 N 15.52, found C

63.04, H 6.89, N 15.32%.

6. X-Ray crystal structure determination

Three-dimensional X-ray data were collected on a Bruker Kappa Apex CCD diffractometer at low temperature for A7, A8,

A12 and A21 by the

φ

-

ω

scan method. Reflections were measured from a hemisphere of data collected from frames each

. Of the 31230 for A7, 45033 for A8, 58473 for A12 and 36222 for A21 reflections measured, all

of them covering 0.3º in

ω

were corrected for Lorentz and polarization effects and for absorption by multi-scan methods based on symmetry-

equivalent and repeated reflections, 5880, 3547, 4420 and 6536, respectively, independent reflections exceeded the

significance level (F/σF) > 4.0. Complex scattering factors were taken from the program package SHELXTL [41]. The

structures were solved by direct methods and refined by full matrix least-squares on F². In A7, hydrogen atoms were

included in calculation positions and refined in the riding mode, except for O(1W), which were located in difference Fourier

map and fixed to oxygen atom. In A8, A12 and A21, hydrogen atoms were located in difference Fourier map and left to

refine freely. Refinements were done with allowance for thermal anisotropy of all non-hydrogen atoms. Further details of

the crystal structure determination are given in Table 1. A final difference Fourier map showed no residual density outside:

0.492 and -0.315 e.Å^–3for A7 and 0.301 and -0.319 e.Å^–3for A8, 0.352 and -0.304 e.Å^–3for A12 and 0.495 and -0.710 e.Å^–3

10 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 12 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

for A21. A weighting scheme w = 1/[σ²(F_o²) + (0.059000 P)²+ 0.058800 P] for A7, w = 1/[σ²(F_o²) + (0.043600 P)²+ 1.793400

P] for A8, w = 1/[σ²(F_o²) + (0.050300 P)²+ 0.339900 P] for A12 and w = 1/[σ²(F_o²) + (0.051800 P)²+ 0.625000 P] for A21,

where

P = +

(|F_o|²2|F_c|²)/3, were used in the latter stages of refinement. CCDC 1007368-1007370

and 1036519 contains the supplementary crystallographic data for the structure reported in this paper. These data can be

obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html, or from the Cambridge Crystallographic

Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223 336 033; or e-mail: deposit@ccdc.cam.ac.uk.

7. Pharmacological Evaluation

7.1. Antiamoebic activity

All the compounds were screened in vitro for antiamoebic activity against HM1:IMSS strain of E. histolytica by micro

dilution method. E. histolytica trophozoites were cultured in wells of 96-well microtiter plate by using Diamond TYIS-33

growth medium [42]. The test compounds (1 mg) were dissolved in ethanol (50 mL, level at which no inhibition of amoeba

occurs) [13, 26]. The stock solutions of the compounds were prepared freshly before use at a concentration of 1 mg/mL.

Each plate included metronidazole as standard amoebicidal drug, negative control (culture medium plus amoeba) and a

blank (culture medium only). All the compounds were used in triplicate concentrations. The parasite suspension was

adjusted to 10⁵cells per mL by adding fresh medium and then distributed to a 96-wells microtiter plate (Corning).

Compounds were added to the respective wells and the plate was sealed, gassed for 10 min with nitrogen and then

incubated at 37 °C for 72 h. After incubation, the amoeba growth was checked under microscope. The culture medium was

removed by inverting the plate and shaking gently. Plate was then immediately washed with sodium chloride (0.9%) at 37

°C, dried at room temperature and the cells fixed with methanol and once dried, stained with aqueous eosin (0.5%) for 15

min. The optical density of the resulting solution in each well was determined at 490 nm in a micro plate reader. The

percentage inhibition of parasite growth was calculated from the optical densities of the control and test compounds. A

non-linear regression analysis was used to determine the best fitting line from which the IC₅₀values were estimated. Each

compound was tested at least in two independent experiments.

7.2 In vitro antimalarial activity

The chloroquine-sensitive strain of P. falciparum (3D7) was maintained continuously in vitro in supplemented RPMI-1640

culture media at 37ºC and gassed with a mixture of 5% CO_2,3% O₂and 92% N₂[44, 45]. The culture was synchronised in the

ring stage with 5% D-sorbitol [46]. To determine the antimalarial activity of the various derivatives, the synchronised ring-

stage parasites were adjusted to a final parasitaemia of 0.5% and 1% haematocrit, to which serial (1:2) dilutions of each

derivative and positive control, chloroquine was added. Negative controls included uninfected erythrocytes and drug-free

parasitized erythrocytes [47]. Following a 24 h incubation period, radiolabeled [³H]-hypoxanthine isotope (Amersham) at a

concentration of 0.5μCi/well was added to each well. The microtiter plate was then incubated for a further 24 h before the

parasitic [³H]-DNA was harvested onto glass fibre filter mats and the β-radioactivity counted. The counts per minute were

expressed as the parasite survival rate taking the uninfected erythrocyte and untreated parasitized controls into account.

Chloroquine was used as the reference agent.

7.3 Inhibition of β-haematin formation

In order to determine if the preliminary mechanism of action of the chloroquinolin-4-yl)piperazine-1-yl] acetamide

derivatives was similar to chloroquine, the ability of the compounds to inhibit the synthetic equivalent of haemozoin, β-

haematin was determined [48]. Derivatives were incubated along with the test/control compound, 1 mg/ml haemin

solubilised in DMSO, and a 0.5 M acetate buffer. The latter was utilized to simulate the acidic conditions (pH 4.7) of the

11

Please do not adjust margins

RSC Advances

Page 13 of 30

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

parasitic food vacuole. The plates were then incubated for 24 h at 37 ºC before the β-haematin crystals were washed with

DMSO to remove the unreacted haemin. The β-haematin crystals were then dissolved in 0.2 M NaOH solution and the

absorbance read at 405 nm. Percentage inhibition of β-haematin crystal formation was determined using the appropriate

negative controls. Chloroquine was used as the positive control.

7.4 Toxicity assays

7.4.1. Cell viability (MTT) assay:

Human embryonic kidney epithelial (HEK-293) cells were maintained at 37 °C in a humidified environment with 5% CO₂as a

monolayer in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% of fetal bovine serum, 100 IU/ml

o

penicillin and 100 μg/ml streptomycin,) [49]. A cell suspension (36,000 cells/well) was incubated at 37 C for 46 h with 50

μM compounds/positive control. A final concentration of less than 1% DMSO had no effect on the viability of the cells.

Thereafter, 20 µl of MTT (5 mg/ml in phosphate buffered saline (pH 7.3)) was added to each well and incubated for a

further 2 h. DMSO was used to dissolve the formazan crystals, and then quantified by reading the absorbance at 540 nm

with a reference wavelength of 690 nm (Labsystems Multiskan RC). Percent cellular viability was determined using the

appropriate controls, with methotrexate and camptothecin used as the positive controls.

7.4.2 Haemolysis assay

A suspension of fresh red blood cells was adjusted to a 1% haematocrit in supplemented RPMI-1640 culture media and

incubated for 48 h along with 25 μl test compound/control (50 μM) [17]. The absorbance of the supernatant was read at

412 nm. The % haemolysis was calculated using a 0.2% Triton X-100 solution as the 100% haemolytic control. Chloroquine

was used as the reference agent.

7.5 Statistical analysis

Each experiment was repeated, at least, in triplicate to calculate the average and standard deviation. The concentration

required to elicit a 50% effect/inhibition was determined using GraphPad Prism^(version 5) using the log sigmoid dose-

response curve (variable slope) equation.

8. Molecular docking

Docking has been used extensively to determine the interacting residues within the binding pocket of enzyme with the

ligand [50-35]. For undertaking docking analysis, the crystal structure of wild-type Plasmodium falciparum dihydrofolate

reductase-thymidylate synthase (PDB id: 1J3I) co-crystallized with ligand (WR99210) was taken [36]. To identify the

residues that show binding with the crystallized analogues (A7, A8, A18 and A21) with PfDHFR Autodock 4.2 as in our

previous study has been used [17]. Docking simulations were performed using Lamarckian Genetic algorithm (LGA) and the

grid maps representing the ligand were calculated with Autogrid. The dimensions of the grid were 60x60x60 grid points

with a spacing of 0.375 Å between the grid points and centered on the ligand (27.71, 6.508 and 58.3 coordinates). Docking

was performed by creating an initial population of 150 individuals, maximum number of evaluation 2,500,000, maximum

number of generations 27,000, rate of gene mutation 0.02, cross-over rate 0.8 and the remaining parameters were set as

default. 10 docking conformations (poses) were generated and the best docked conformation was selected based on the

Autodock binding energy. Further, the hydrogen and hydrophobic interactions between ligand-receptor complexes were

identified using Ligplot [54].

12 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 14 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

Conclusions

The present study indicates that the compounds consisting of 4-aminochloroquinoline and acetamide linked via piperazine

is a viable combination as it acts against both HM1:IMSS strain of E. histolytica and 3D7 strain of P. falciparum.

Antiamoebic activity indicated that out of twenty seven compounds, eleven exhibited more potent activity than the

standard drug metronidazole (IC₅₀= 1.8 µM). Although all compounds inhibited P. falciparum growth, compounds A25 and

A22 showed the most promising results. But the safety profile of A25 indicated that it should be further investigated as a

lead compound for further derivatisation to improve antimalarial activity and retain safety profile.

Acknowledgements

One of the authors AI is thankful to University Grant Commission, India for providing BSR meritorious fellowship. The

Faculty of Health Sciences Research Office of the University of the Witwatersrand for financial support. This work is based

on the research supported in part by the National Research Foundation of South Africa for the Grant No. 87669. Any

opinion, finding and conclusion or recommendation expressed in this material is that of the author(s) and the NRF does not

accept any liability in this regard.

Notes and references

[1] J. Thwing, J. Skarbinski, R. D.Newman,; Barber, A. M. Mali, J. M. Roberts, L. Slutsker, P. M. Arguin, Surveil. Summ. 2007,

56, 23.

[2] WHO, World Malaria Report, 2013.

[3] WHO Expert Committee on Malaria, WHO Technical Report Series 20th Report, 2000.

[4] A. Kumar, S. B. Katiyar, A. Agarwal, P. M. S. Chauhan, Curr. Med. Chem. 2003, 10, 1137.

[5] R. N.Price, F.Nosten, Drug Resist. Update 2001, 4, 187.

[6] WHO, Guidelines for the Treatment of Malaria, 2010.

[7] C. Smith Gueye, G. Newby, J. Hwang, A.A. Phillips, M. Whittaker, J.R. MacArthur, R.D. Gosling, R.G.A Feachem, Malaria J.

2014, 13, 286

[8] S.M. Taylor, J.J. Juliano, J. Infect. Dis. 2014, 210, 335.

[9] P. Garner, P. M. Graves, PLoS Med. 2005, 2,105.

[10] N. C. Araújo, V. Barton, M. Jones, P. A.Stocks, , S. A. Ward, J.Davies, P.G.Bray, A. E.Shone, M. L Cristiano, P. M. O’Neill,

Bioorg. Med. Chem. Lett. 2009, 19, 2038.

[11] O. Dechy-Cabaret, F. Benoit-Vical, A. Robert, B. Meunier, ChemBioChem 2000, 1, 281

[12] M.L.M Gonzales. L.F Dans, EG Martinez, Cochrane Database Sys Rev. 2009, 15, CD006085

[13] A.T. Keene, A.Harris, J.D.Phillipson, D.C. Warhurst, Planta Med.1986, 52, 278

[14] F. Mansour -Ghanaei, N. Dehbashi , K Yazdanparast, A. Shafaghi, World. J Gastroenterol. 2003, 9, 1832.

[15] (a) D. S. Barnett and R. Kiplin Guy Chem. Rev. 2014, 114, 11221; (b) M. Njoroge, N. M. Njuguna, P. Mutai , D.S. B.

Ongarora, P. W. Smith, and K. Chibale Chem. Rev. 2014, 114, 11138

[16] (a). F. Hayat, A. Salahuddin, J. Zargan, A. Azam, Eur. J. Med. Chem. 2010, 45, 6127 (b). F. Hayat, E. Moseley, A.

Salahuddin, R.L.Van Zyl, A. Azam, Eur. J. Med. Chem. 2011, 46 , 1897

[17] (a) A. Salahuddin, A. Inam, R.L. Van Zyl, D.C. Heslop , C. T. Chen , F. Avecilla, S.M. Agarwal, A. Azam Bioorg. Med.

Chem. 2013, 21, 3080 (b) A. Inam, SM Siddiqui, TS Macedo, DRM Moriera, AC Lima Liete, MBP Soares, A Azam; Eur. J. Med.

13

Please do not adjust margins

RSC Advances

Page 15 of 30

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

Chem. 2014, 75, 67-76. (c) Nava-Zuazo, S.E. Soto, J.G. Alvarez, I. L. Rivera, G.M.M. Salinas, S.S. Fernandez, M.J. Chan-Bacab,

R.C.Rivera, R. Moo-Puc, G.M.Lopez, G.N.Vazquez; Bioorg. Med. Chem., 2010, 18, 6398–6403

[18] (a) Simeon Andrews, Steven J. Burgess, Deborah Skaalrud, Jane Xu Kelly, David H. Peyton, J Med Chem. 2010, 53, 916

(b)V.K. Agrawal, S. Sharma, Indian J. Chemistry 1987, 26b, 550.

[19] M. Garcia-Viloca, D.Truhlar, Gao, J. Biochem. 2003, 42, 13558.

[20] A. Gangjee, H.D.Jain, S. Kurup, Med. Chem. 2007, 7, 524

[21] (a) G. Rastelli, S. Pacchioni, W. Sirawaraporn, R. Sirawaraporn, M. D. Parenti, A. M. Ferrari, J. Med. Chem. 2003, 46,

2834. (b) S. Madapa, Z. Tusi, D. Sridhar, A. Kumar, M.I. Siddiqi, K. Srivastava, A. Rizvi, R. Tripathi, S. K. Puri, G.B. Shiva

Keshava, P. K. Shukla, S. Batra, Bioorg. Med. Chem., 2009, 17, 203.

[22] (a) Cho, S.; Park, Y.; Kim, J.; Lee, S.; Ma, C.; Song, S.; Joo, W.; Falck, J. R.; Shiro, M.; Dong-Soo Shin, D.; Yoon, Y. A. J. Org.

Chem. 2003, 68, 7918. (b) S. Ganguly, K. Somakala, J. Inst. Chemists (India), 2007, 79, 33.

[23] M. S. Balakrishna, P. P. George and J. T. Mague, J. Chem. Research, 2003, 576

[24] Z. Xiaohe, Q. Yu, Y. H,S. Xiuqing and Z. Rugang, Chem Biol Drug Des 2010; 76, 330-339

[25] J. Qinggang , D. Yang , X. Wang , C. Chen, Q. Deng , G. Zhiqiang , L. Yuan a , Xiaolan Yang, F. Liao; Bioorg. Med. Chem.

2014, 22, 3405–3413

[26] Gonzalez-Rosende, M. E.; Olivar, T.; Castillo, E.; Sepulveda-Arques, J. Arch. Pharm. 2008, 341, 690-695.

[27] H. Behbehani, and H. M.Ibrahim, Molecules 2012, 17, 6362-6385

[28] R. Kumar, M. Kaur , M. S. Bahia, Om Silakari, Eur. J. Med. Chem. 2014, 80, 83-91.

[29] T. R. K. Reddy , C. Li, X. Guo, P. M. Fischer, L. V. Dekker, Bioorg. Med. Chem. 2014, 22, 5378–5391

[30] Jain NP , Upasani CD , Kalkotwar RS and Jain UN, Research Journal of Pharmaceutical, Biological and Chemical Sciences,

2013, 3, 1470-1480.

[31] Chen Hong , Wen Luo, , Dong Yao, Ya-Bin Su, Xin Zhang, Run-Guo Tian, Chao-Jie Wang Bioorg. Med. Chem. 2014, 22

3213–3219

[32] Mingming Zhang, Weiliang Zhu, Yingxia Li, Eur. J. Med. Chem. 2013, 62, 301-310.

[33] Cunlong Zhang , Chunyan Tan , Xuyu Zu , Xin Zhai , Feng Liu , Bizhu Chu, Xiaohua Ma, Yuzong Chen, Ping Gong,

Yuyang Jiang , Eur. J. Med. Chem. , 2011, 46, 1404-1414

[34] Colabufo, Nicola Antonio; Berardi, Francesco; Perrone, Roberto; Rapposelli, Simona; Digiacomo, Maria; Vanni,

Michael; Balsamo, Aldo, J Med Chem. 2008, 51, 7602-13.

[35] Stephen J. Shuttleworth, Daniel Nasturica, Christian Gervais, M. Arshad Siddiqui, Robert F. Rando and Nola Lee, Bioorg

Med. Chem. Lett., 2000, 10, 2501-2504.

[36] Brown, Dennis A.; Kharkar, Prashant S.; Parrington, Ingrid; Reith, Maarten E. A.; Dutta, Aloke K., J. Med. Chem. 2008,

51, 7806–7819

14 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 16 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

[37] Pablo Wessig and Kristian Möllnitz, J. Org. Chem. 2008, 73, 4452–4457.

[38] Wu, Chun-Fang; Zhao, Xin; Lan, Wen-Xian; Cao, Chunyang; Liu, Jin-Tao; Jiang, Xi-Kui; Li, Zhan-Ting, J. Org. Chem. 2012,

77, 4261−4270.

[39] Musso, David L.; Cochran, Felicia R.; Kelley, James L.; McLean, Ed W.; Selph, Jeffrey L.; Rigdon, Greg C.; Orr, G. Faye;

Davis, Ronda G.; Cooper, Barrett R.; Styles, Virgil L.; Thompson, James B.; Hall, William R., J. Med. Chem., 2003, 46, 3-6.

[40] Christian Jö st, Christoph Nitsche, Therese Scholz, Lionel Roux, and Christian D. Kle J. Med. Chem. 2014, 57, 7590−7599

[41] G. M. Sheldrick, SHELXL-97: An Integrated System for Solving and Refining Crystal Structures from Diffraction Data

(Revision 5.1); University of Göttingen, Germany, 1997.

[42]. L.S. Diamond, D.R. Harlow, C. Cunnick, Trans. Soc. Trop. Med. Hyg. 1978, 72, 431

[43] F.D. Gillin, D.S. Reiner, M. Suffness, Antimicrob. Agents Chemother. 1982, 22, 342

[44] J.B. Jensen, W. Trager, Science 193, 1976, 673

[45]. R.L. Van Zyl, S.T. Seatlholo, A.M. Viljoen, S. A. J. Botany, 2010, 76, 667

[46]. C. Lambros, J.P. Vanderberg, J. Parasitol. 1979, 65, 418

[47]. R.E. Desjardins, C.J. Canfield, J.D. Haynes, J.D. Chulay, Antimicrob. Agents Chemother. 1979, 16, 710

[48]. S.M. Chemaly, C.-T. Chen, R.L. van Zyl, J. Inorg. Biochem. 2007, 101, 764

[49] T. J. Mosmann, Immunol. Methods 1983, 65, 55.

[50] I.S. Yadav , P.P. Nandekar , S. Srivastavaa, A. Sangamwar, A. Chaudhury, S.M. Agarwal Gene. 2014, 539, 82

[51] A. Salahuddin, S. M. Agarwal, F. Avecillac, A. Azam Bioorg. Med. Chem. Lett. 2012, 22, 5694

[52] S.M. Agarwal, R. Jain, A. Bhattacharya, A.Azam, Int. J. Parasitol 2008, 38, 137

[53] J Yuvaniyama, P Chitnumsub, S Kamchonwongpaisan, J Vanichtanankul, W Sirawaraporn, P Taylor, MD Walkinshaw, Y

Yuthavong. Nat Struct Biol. 2003, 10, 357

[54] A.C. Wallace, R.A. Laskowski, J.M. Thornton, Protein Eng. 8, 1995, 127

15

Please do not adjust margins

Page 17 of 30

RSC Advances

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

Caption to Illustration

Caption Heading

Figure 1.- ORTEP plot for the compounds (A7, A8, A12, A21). All the non-hydrogen atoms are

presented by their 30% probability ellipsoids. Hydrogen atoms are omitted for clarity.

Figure 2.- Intermolecular π-π interactions in A7. Dashed lines link the centres of the π clouds

involving in each interaction

Figure 3.- Intermolecular π-π interactions in A21. Dashed lines link the centres of the π clouds

involving in each interaction

Figure 4: Ligplot showing hydrogen bonding interaction and hydrophobic contacts (with green

dashed lines and red arcs with radiating lines respectively) for the ligand (A) A7 (B) A8 (C) A18 and

(D) A21.

Scheme1: Synthesis of substituted chloro acetamides (1-27) and 2-[4-(7-chloro-quinolin-4-yl)-

piperazin-1-yl]acetamides (A1-A27)

Table 1. Crystal data and structure refinement for 2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-(4-

fluorophenyl)acetamide (A7), for

2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-p-tolylacetamide

(A8), for 2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-o-tolylacetamide (A12) and 2-(4-(7-

chloroquinolin-4-yl)piperazine-1-yl)-1-(4-(2,3-dichlorophenylpipezin-1-yl)- ethanone (A21).

Table 2. Antiparasitic activity and toxic effects of 2-[4-(7-chloroquinolin-4-yl)piperazine-1-

yl]acetamide derivatives A1-A27

16 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 18 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

(a)

17

Please do not adjust margins

Page 19 of 30

RSC Advances

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

(b)

(c)

18 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 20 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

(d)

Figure 1: ORTEP plot for the compounds A7 (a), A8 (b), A12 (c), A21 (d) respectively. All the non-

hydrogen atoms are presented by their 30% probability ellipsoids. Hydrogen atoms are omitted for

clarity.

19

Please do not adjust margins

RSC Advances

Page 21 of 30

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

Figure 2.- Intermolecular π-π interactions in A7. Dashed lines link the centres of the π clouds involving in each

interaction

.

Figure 3.- Intermolecular π-π interactions in A21. Dashed lines link the centres of the π clouds involving in each

interaction.

20 | J. Name., 2015, 00, 1-3

This journal is © The Royal Society of Chemistry 20xx

Please do not adjust margins

RSC Advances

Page 22 of 30

View Article Online

DOI: 10.1039/C5RA05472A

Journal Name

Scheme1:

Synthesis

of

substituted

chloro

acetamides

(1-27)

and

2-[4-(7-chloro-quinolin-4-yl)-piperazin-1-yl]acetamides (A1-A27)

NH

ArNH₂

Cl

(a)

+

Cl

Ar

Cl

O

(1-15)

Cl

N

(b)

Cl

R₁

X

HN

+

X

O

R₁

(X= N, C)

RNH₂

(16-22)

NH

O

(b)

Cl

+

Cl

R

O

(23-27)

Cl

NH

N

Ar

O

H

N

(A1-A15)

Cl

(d)

Cl

N

(c)

N

X

O

R₁

Cl

(A16-A22)

NH

N

R

O

(A23-A27)

Reagents and conditions : (a) glac.AcOH, sat. NaOAc solution (b) Et₃N, CH₂Cl₂(c)piperazine, EtOH,

reflux (d) K₂CO₃, cat. KI, DMF, reflux

21

Please do not adjust margins

RSC Advances

Page 23 of 30

View Article Online

DOI: 10.1039/C5RA05472A

COMMUNICATION

Journal Name

Table 1. Crystal data and structure refinement for 2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-(4-

fluorophenyl)acetamide.H₂0 (A7), for 2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-p-tolylacetamide

(A8), for 2-(4-(7-chloroquinolin-4-yl)piperazine-1-yl)-N-o-tolylacetamide (A12) and 2-(4-(7-

chloroquinolin-4-yl)piperazine-1-yl)-1-(4-(2,3-dichlorophenylpipezin-1-yl)- ethanone (A21).

A7

A8

A12

C₂₂H₂₃ClN₄O

394.89

A21

Formula

Formula weight

T, K

C₂₁H₂₂ClFN₄O₂

416.88

C₂₂H₂₃ClN₄O

394.89

100(2)

C₂₅H₂₆Cl₃N₅O

518.86

100(2)

Wavelength, Å

Crystal system

Space group

a/Å

0.71073

Triclinic

P1

0.71073

Orthorhombic

Pbca

0.71073

Triclinic

P1

0.71073

Monoclinic

P2₁/n

6.7737(3)

9.6448(3)

15.8855(6)

97.023(2)

97.739(2)

107.511(2)

966.05(6)

2

18.2066(10)

11.0845(6)

19.4301(10)

90

9.0751(4)

9.2785(4)

14.1227(8)

105.382(3)

92.801(3)

119.213(2)

978.02(8)

2

9.6408(3)

12.9637(3)

19.8442(5)

90

b/Å

c/Å

α/º

β/º

90

98.1580(10)

90

γ/º

90

V/Å³

3921.2(4)

8

2455.04(11)

4

Z

F₀₀₀

436

1664

416

1080

D_calc/g cm^-3

1.433

1.338

1.341

1.404

/mm^-1

0.234

0.215

0.216

0.402

ꢀ

1.31 to 34.60

0.0467

2.38 to 27.51

0.0485

1.53 to 29.38 2.24 to 30.64

0.0456 0.0252

θ

/ (º)

R_int

Crystal size/ mm³

0.50 x 0.47 x 0.38

0.50

0.35

1.025

x

0.45

x

0.43 x 0.30 x 0.4 x 0.5 x 0.5

0.25

Goodness-of-fit on F²

R₁[I>2σ(I)]^a

wR₂(all data) ^b

1.082

1.064

1.039

0.0474

0.1267

0.0350

0.0942

0.0375

0.1047

0.0342

0.0947

Largest differences peak 0.492 and -0.315

and hole (eÅ^-3)

0.301 and -0.319 0.352 and

-

0.495 and -0.710

0.304

4

^aR₁= ΣF_o - F_c/ΣF_o. ^bwR₂= {Σ[w(F_o²-F_c²)²]/Σ[w(F_o)]}^1/2

22 | J. Name., 2015, 00, 1-3

Please do not adjust margins

RSC Advances

Page 24 of 30

Please do not adjust margins

Journal Name

COMMUNICATION

Table 2. Antiparasitic activity and toxic effects of 2-[4-(7-chloroquinolin-4-yl)piperazine-1-yl]acetamide derivatives A1-A27

Antiamoebic

Activity¹

Cytotoxic

activity

(% cell death to chloroquine at

Haemolytic

(ratio of lysis relative

activity

Antimalarial

activity²

(IC₅₀± s.d.: µM.)

Inhibition

of

β-

Compound

A 1

R

haematin formation³

(IC₅₀value: µM)

(IC₅₀

units

±

S.D.)

at 50 µM)

50 µM)

2.25±0.03

3.95±1.21

44.60±10.57

1.04

54.41±1.07

34.57±1.78

O

A 2

A3

7.90±0.02

29.29±7.01

81.86±3.32

28.84±5.35

0.98

0.52

O

F

1.38±0.02

1.17±0.02

13.24±3.24

17.96±3.93

110.32±18.93

55.62±5.76

F

A 4

54.40±3.48

0.61

O

23

Please do not adjust margins

Page 25 of 30

RSC Advances

Please do not adjust margins

COMMUNICATION

Journal Name

A 5

6.40±0.02

14.60±2.35

67.33±0.64

0.53

43.98±3.77

O

F

A 6

A 7

3.20±0.01

19.12±1.63

6.72±1.45

37.17±5.87

48.63±4.15

0.66

1.03

44.86±0.60

75.51±1.71

0.41±0.02

F

A 8

1.60±0.02

0.72±0.01

2.84±0.50

50.24±6.10

41.22±6.45

0.51

0.72

40.36±3.68

46.53±5.89

CH₃

A 9

33.26±7.74

CH₃

24 | J. Name., 2015, 00, 1-3

Please do not adjust margins

RSC Advances

Page 26 of 30

Please do not adjust margins

Journal Name

COMMUNICATION

A 10

5.90±0.02

7.20±0.02

14.66±2.72

27.53±10.61

71.72±1.34

0.67

0.55

68.79±5.95

71.43±7.91

Cl

A11

14.98±2.35

Br

CH₃

A12

A 13

A14

5.90±0.01

17.14±0.02

1.49±0.01

33.52±3.85

6.26±1.53

16.42±1.41

54.76±3.33

28.98±8.49

65.08±2.12

0.68

0.45

0.48

95.98±13.81

49.30±7.72

34.28±2.69

H₃C

CH₃

25

Please do not adjust margins

Page 27 of 30

RSC Advances

Please do not adjust margins

COMMUNICATION

Journal Name

A15

7.30±0.01

2.15±0.01

16.92±1.33

43.10±2.98

54.39±3.43

0.57

0.88

62.81±3.21

Cl

N

F

N

A16

11.72±2.71

23.20±5.17

17.27±0.77

N

A17

1.13±0.02

77.42±3.20

0.52

42.06±2.02

Cl

N

A18

A19

0.52±0.02

10.61±1.41

3.91±0.82

70.31±2.57

61.06±7.75

1.50

1.01

33.32±2.10

38516±7.75

N

BOC

O

N

O

3.24±0.01

26 | J. Name., 2015, 00, 1-3

Please do not adjust margins

RSC Advances

Page 28 of 30

Please do not adjust margins

Journal Name

COMMUNICATION

N

A 20

1.80±0.01

15.55±0.58

36.28±3.83

63.57±2.63

0.74

1.96

> 191.73

Cl

A 21

2.70±0.01

8.35±1.62

64.07±5.44

Cl

N

A22

A23

18.99±0.02

0.35±0.03

70.78±4.39

63.97±3.69

1.65

0.71

35.24±3.16

38.06±3.36

OH

0.86±0.03

16.63±5.26

A 24

A 25

1.43±0.01

17.88±0.62

37.76±1.67

40.07±2.91

1.25

0.78

53.29±3.09

32.24±3.63

2.40±0.035

0.30±0.03

27

Please do not adjust margins

Page 29 of 30

RSC Advances

Please do not adjust margins

COMMUNICATION

Journal Name

A26

4.40±0.02

9.23±3.24

26.17±4.30

0.45

106.65±19.13

A 27

3.55±0.02

1.80±0.01

n.a.

13.64±1.79

n.a.

54.55±2.83

38.97±4.08

1.05±1.27.

74.65±1.50

1.19

n.a.

1.00

n.a.

35.44±4.48

n.a.

Metronidazole

Chloroquine

Camptothecin

0.0013±0.0003

15.32±1.77

n.a.

2

Strains

used

¹HM1:IMSS"

of

E.histolytica,

3D7

of

P.falciparum"

and

³HEK-293

kidney

epithelial

cells.

28 | J. Name., 2015, 00, 1-3

Please do not adjust margins

Article Doi

Chloroquinoline-acetamide hybrids: A promising series of potential antiprotozoal agents

DOI: 10.1039/c5ra05472a

Source and publish data:

Authors:

Article abstract of DOI:10.1039/c5ra05472a

Full text of DOI:10.1039/c5ra05472a

Products guided by the article

R&D Labs maybe for 1131-01-7

Relevant to this article

Hot Product